Every 8-K that Biomarin Pharmaceutical Inc (BMRN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BMRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMRN filings page.
BioMarin Pharmaceutical Inc. (BMRN) has completed the previously announced acquisition of Alesta Therapeutics B.V. under a Share Purchase Agreement. The transaction closed on August 31, 2026, resulting in Alesta becoming a wholly owned subsidiary of BioMarin.
The Share Purchase Agreement was originally entered into on August 18, 2026 among BioMarin, Alesta’s shareholders, Anaheim SpinCo B.V., and Shareholder Representative Services LLC, acting as representative of the Alesta equityholders.
BioMarin Pharmaceutical Inc. (BMRN) entered into a binding term sheet with Ascendis Pharma A/S for a global settlement and license related to BioMarin’s C‑type natriuretic peptide patent portfolio. BioMarin will grant Ascendis a non‑exclusive, worldwide, transferable, royalty‑bearing license covering Yuviwel (TransCon CNP/navepegritide) for all current and potential indications, including achondroplasia and hypochondroplasia, and for combination use with other medicines.
In return, Ascendis will pay BioMarin a 20% royalty on annual net sales of licensed products in the U.S. and 18% on annual net sales in the EU, Brazil and South Korea, in each case from first commercial sale (retroactively, as applicable) through May 2030. The settlement provides for dismissal with prejudice of all pending patent-related proceedings between the companies worldwide, includes covenants not to challenge or sue on the relevant patents, and a mutual regulatory non‑interference clause. The term sheet is immediately binding and will remain in force even if a more detailed settlement and license agreement is not finalized by September 24, 2026.
BioMarin Pharmaceutical Inc. is entering into a definitive agreement to acquire Alesta Therapeutics B.V. via a share purchase transaction on a cash‑free, debt‑free basis. Alesta shareholders will receive an upfront cash payment of $275 million, plus up to $215 million in additional payments tied to development and regulatory milestones. Closing is targeted for the third quarter of 2026, subject to customary conditions, including a pre‑closing spinout of Alesta’s non‑ALE1 assets into a separate entity and the absence of legal orders blocking completion.
The acquisition gives BioMarin rights to ALE1, an orally active small molecule in an ongoing Phase 1/2a trial for hypophosphatasia (HPP), a rare genetic bone disease. ALE1 is positioned as a potential first oral therapy targeting the disease‑central metabolite PPi. BioMarin plans to fund the deal with cash on hand and expects the transaction, excluding the upfront consideration, to be modestly dilutive to 2026 financial results. Following closing, ALE1 will join BioMarin’s Skeletal Conditions Business Unit, supporting its strategy to expand into larger rare disease markets.
BioMarin Pharmaceutical Inc. reported strong top-line growth for the quarter ended June 30, 2026, with total revenues up 20% year-over-year to $990 million, driven by contributions from newly acquired GALAFOLD and POMBILITI + OPFOLDA, VOXZOGO growth, and higher PALYNZIQ sales. VOXZOGO revenue rose to $253 million, and Metabolic Conditions revenue benefited from the Amicus acquisition despite softer ALDURAZYME and timing-related government orders.
Profitability declined as GAAP net income fell to $45 million from $241 million and Non-GAAP income to $236 million from $282 million, reflecting Amicus-related integration and restructuring costs, higher amortization, and increased interest expense on new debt. Full-year 2026 guidance was raised for total revenues ($3.875–$3.925 billion), VOXZOGO ($1.0–$1.05 billion), and Non-GAAP diluted EPS ($4.90–$5.10). The company targets about $280 million GAAP cost reductions from Amicus by 2028 and gross leverage below 2.5x by mid-2027, while advancing an expanded rare-disease pipeline, including VOXZOGO label expansions and new programs, and discontinuing BMN 401.
BioMarin Pharmaceutical Inc. filed an amendment to its prior acquisition report to add full historical financial statements for Amicus Therapeutics and unaudited pro forma combined financials reflecting Amicus as a wholly owned subsidiary. The audited Amicus statements show 2025 net product sales of $634.2 million, driven by Galafold and Pombiliti + Opfolda, and a net loss of $27.1 million. Total assets were $949.9 million, including $214.0 million of cash and cash equivalents and $79.5 million of marketable securities, against long‑term debt of $392.7 million under a senior secured term loan due 2029. The notes describe Amicus’ pending cash Merger Agreement with BioMarin at $14.50 per share, its rare‑disease product portfolio, significant tax attributes, and key collaborations and obligations.
BioMarin Pharmaceutical Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the company’s 2017 Equity Incentive Plan, increasing the number of common shares reserved for issuance under the plan by 7,650,000 shares.
All ten director nominees were elected to serve until the next annual meeting. Stockholders also ratified the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.
BioMarin Pharmaceutical Inc. reported first-quarter 2026 results and raised its full-year 2026 revenue outlook. Total revenues were $766 million, up 3% year-over-year, driven by Enzyme Therapies and more patients starting VOXZOGO. GAAP net income fell to $106 million, with Non-GAAP income at $149 million, reflecting higher selling, R&D and manufacturing costs, including a $31 million NAGLAZYME manufacturing charge.
The company increased 2026 total revenue guidance to $3.825–$3.925 billion, mainly from adding GALAFOLD and POMBILITI + OPFOLDA after completing the Amicus acquisition. Enzyme Therapies revenue guidance rose by $500 million, while Non-GAAP diluted EPS guidance edged to $4.85–$5.05. Operating cash flow was $221 million in the quarter, and the company secured about $3.7 billion of new non-convertible debt to fund the Amicus transaction.
BioMarin Pharmaceutical Inc. completed its previously announced acquisition of Amicus Therapeutics, buying all Amicus shares for $14.50 in cash per share, implying total equity value of about $4.8 billion. Amicus now operates as a wholly owned subsidiary.
To fund the cash deal, BioMarin entered into new senior secured credit facilities consisting of a $2.0 billion Term Loan B, a $800.0 million Term Loan A, and a $600.0 million revolving credit facility, alongside its previously issued 5.500% Senior Notes due 2034 and cash on hand. The term loans were fully drawn at closing, while the revolver remains available for working capital and general corporate purposes.
The new credit agreement is secured by a first‑priority lien on substantially all assets of BioMarin and certain subsidiaries and includes financial covenants, including a Total Net Leverage Ratio cap of 3.50 to 1.00 (temporarily 4.00 to 1.00 in some acquisition scenarios) and a minimum Interest Coverage Ratio of 3.00 to 1.00. With Amicus, BioMarin adds marketed rare‑disease therapies Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, plus U.S. rights to late‑stage candidate DMX‑200 for focal segmental glomerulosclerosis.
BioMarin Pharmaceutical Inc. reports that France’s Ministry of Economics and Finance has granted foreign direct investment clearance for its planned merger with Amicus Therapeutics. This French FDI clearance satisfies the final outstanding regulatory condition under the Merger Agreement, aside from items to be completed at closing.
The merger, in which Amicus will become a wholly owned subsidiary of BioMarin, is expected to close on April 27, 2026. The companies caution that this timing and other expectations are forward-looking and subject to risks described in their SEC filings and the Amicus merger proxy.
BioMarin Pharmaceutical Inc. is halting dosing and enrollment in its Phase 2 trials of VOXZOGO for Turner syndrome, SHOX-deficiency and Aggrecan (ACAN)-deficiency. This decision follows several slipped capital femoral epiphysis (SCFE) events reported in two ongoing investigator-sponsored trials using VOXZOGO in these conditions.
BioMarin states that SCFE has not been seen in its own Phase 2 trials in these indications, nor among more than 5,000 infants and children treated with VOXZOGO for achondroplasia over about 10,000 patient-years of clinical and post-marketing safety data. No SCFE cases have appeared in VOXZOGO trials for hypochondroplasia. The Phase 2 CANOPY trials of VOXZOGO will continue for children with Noonan syndrome and for most participants with idiopathic short stature without ACAN-deficiency.
BioMarin Pharmaceutical reported strong growth for 2025 and set higher profit goals for 2026 while reshaping its portfolio. Total revenues rose 13% to $3.221 billion, with fourth quarter revenues up 17% to $875 million. Growth was led by VOXZOGO, which delivered 26% full‑year revenue growth to $927 million, and Enzyme Therapies, up 9% to $2.105 billion.
Full‑year GAAP net income was $348.9 million and Non‑GAAP Income was $614 million, equal to Non‑GAAP diluted EPS of $3.15. Fourth quarter GAAP results showed a $47 million net loss due to approximately $240 million of charges tied to voluntarily withdrawing ROCTAVIAN from the market. Non‑GAAP income for the quarter was $89 million.
BioMarin announced a definitive agreement to acquire Amicus Therapeutics, adding Galafold and Pombiliti + Opfolda, and has secured about $3.7 billion of non‑convertible debt financing. For 2026, excluding any post‑close Amicus contribution, the company guides to total revenues of $3.325–$3.425 billion and Non‑GAAP diluted EPS of $4.95–$5.15, with an expected Non‑GAAP operating margin of about 40%.
BioMarin Pharmaceutical Inc. has closed a private offering of $850 million in 5.500% senior unsecured notes due 2034. The issue price was 100.000%, and the notes were sold to qualified institutional buyers and certain non-U.S. investors.
BioMarin plans to use the net proceeds, together with a new $2 billion senior secured term loan B facility, a $800 million term loan A facility and cash on hand, to fund the pending acquisition of Amicus Therapeutics, Inc. and related fees and expenses. It also expects to enter into a $600 million senior secured revolving credit facility and may borrow up to $150 million under it for transaction costs.
Offering proceeds are held in escrow until the Amicus acquisition closes. If the deal is not completed on or before December 19, 2026, or certain other events occur, BioMarin must redeem the notes at 100% of the initial issue price plus accrued interest. The notes are guaranteed by certain subsidiaries and are subject to covenants limiting additional debt, dividends, liens, asset sales and mergers.
BioMarin Pharmaceutical Inc. is raising debt financing to help fund its pending acquisition of Amicus Therapeutics. The company agreed to sell $850 million of 5.500% senior unsecured notes due 2034 in a private offering to qualified institutional buyers and non‑U.S. persons.
BioMarin also completed syndication of a new $2 billion senior secured term loan B facility, in addition to a previously arranged $800 million senior secured term loan A facility, and expects to enter into a $600 million senior secured revolving credit facility. It plans to use net proceeds from the notes, together with borrowings under the term facilities and cash on hand, to pay the Acquisition consideration and related fees and expenses. If the Acquisition is not completed by December 19, 2026, BioMarin must redeem the notes at 100% of their initial issue price plus accrued interest.
BioMarin Pharmaceutical Inc. estimates that it generated approximately $3.2 billion in total revenues (unaudited) for the year ended December 31, 2025, including about $920 million from sales of VOXZOGO®. As of December 31, 2025, it reports approximately $2.1 billion in cash, cash equivalents and investments, all on a preliminary, unaudited basis.
The company also announces plans to offer $850 million of senior unsecured notes due 2034 in a private placement and to arrange a $2 billion Term Loan B facility, a $800 million Term Loan A facility, and a $600 million new revolving credit facility. Together with potential borrowings of up to $150 million under the revolver, these financings are intended to fund the pending acquisition of Amicus Therapeutics, Inc. and related costs. BioMarin is providing supplemental risk factors and unaudited pro forma combined financial information to illustrate the impact of the acquisition and financing.
BioMarin Pharmaceutical Inc. provided a preliminary financial update alongside its presentation at the J.P. Morgan Healthcare Conference. Based on unaudited results, the company estimates it generated approximately $3.2 billion in total revenues for the year ended December 31, 2025, including about $920 million from VOXZOGO® sales for the same period. BioMarin also expects an asset write-down related to ROCTAVIAN in the fourth quarter of 2025 of approximately $230 million to $260 million.
Of this write-down, around $120 million to $125 million, or roughly $(0.60) to $(0.64) per diluted share assuming about 200 million weighted-average diluted shares outstanding, is expected to reduce the company’s Non-GAAP Income and Non-GAAP Diluted EPS for 2025. Excluding the impact of this asset write-down, BioMarin states that its previously issued full-year 2025 Non-GAAP Diluted EPS guidance remains unchanged. All figures are preliminary, unaudited, and subject to normal year-end closing procedures.
BioMarin Pharmaceutical Inc. reported that it has appointed Rashmi Ramchandani as Vice President, Chief Accounting Officer, effective January 19, 2026. In this role she will also become the company’s principal accounting officer, while Brian Mueller will remain Executive Vice President, Chief Financial Officer and principal financial officer.
Ramchandani brings more than two decades of accounting and finance experience, including senior roles at Gilead Sciences and Strava, and is a CPA with a BA in Accounting and Psychology. Her compensation package includes a $460,000 annual base salary, a $400,000 sign-on bonus, eligibility for an annual bonus targeted at 45% of base salary starting in 2026, and equity awards of restricted stock units valued at $1,050,000 and $400,000 plus stock options valued at $450,000, all subject to time-based vesting and continued service.
The sign-on bonus must be repaid if her employment ends within two years under most circumstances, and the company states she has no related party transactions requiring disclosure.
BioMarin Pharmaceutical Inc. announced financial results for the third quarter ended September 30, 2025. The company furnished a press release dated October 27, 2025 as Exhibit 99.1.
The press release is furnished and not deemed filed, and the company also included the cover page Inline XBRL data as Exhibit 104.
BioMarin Pharmaceuticals filed an 8-K disclosing its use and definition of Non-GAAP Diluted EPS and related Non-GAAP measures. The filing explains Non-GAAP Diluted EPS as Non-GAAP Income divided by Non-GAAP weighted-average diluted shares outstanding, and defines reconciling adjustments that may exclude amortization of intangible assets, stock-based compensation expense and certain other specified items, plus an estimated tax impact for those adjustments. The company says it uses both GAAP and Non-GAAP results internally to assess operating performance and guide business decisions in its core activities: discovery, development, manufacture, marketing and sale of biologic therapies. The filing cautions that these measures are not prepared under GAAP, have no standardized meaning, and may be calculated differently than similarly named metrics at other companies.
BioMarin Pharmaceutical Inc. announced that Erin Burkhart, Group Vice President and Chief Accounting Officer, notified the company of her voluntary resignation effective September 2, 2025. The company will search for a successor and, if none is appointed by the effective date, Brian Mueller, Executive Vice President and Chief Financial Officer, will serve as principal accounting officer in addition to his CFO duties. The filing states Ms. Burkhart's departure is not due to any disagreement with the company. Mr. Mueller will not receive additional compensation for performing the accounting officer role and has no reportable related-party transactions.